Infliximab and adalimumab for the treatment of Crohn's disease

Review proposal consultation

Stakeholder matrix (PDF 229 KB)

Review proposal paper (PDF 171 KB)

Review update March 2015 information

Crohn's disease - infliximab (review) and adalimumab: review decision - March 2011 information

Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 96 KB)

Review Proposal - January 2011 information

Appendix A: provisional matrix of stakeholders (PDF 83 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 135 KB)

Appendix A: provisional matrix of stakeholders (PDF 83 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 135 KB)

NICE recommends two more treatments for Crohn's disease information

Download PDF version information

2010-52 NICE recommends two more treatments for Crohn?s disease (PDF 69 KB)

Crohn's disease - infliximab (review) and adalimumab: final appraisal determination information

Crohn's disease - infliximab (review) and adalimumab: final appraisal determination document (PDF 181 KB)

Response to consultee and commentator comments and the response and comments to the website consultation on the Appraisal Consultation Document (PDF 238 KB)

Consultee and commentator comments on the ACD

Abbott (PDF 64 KB)

National Association for Colitis and Crohn's Disease (PDF 51 KB)

Royal College of Physicians & British Society of Gastroenterology (PDF 43 KB)

Schering Plough (PDF 83 KB)

Royal College of Nursing (PDF 26 KB)

Welsh Assembly Government (WAG) (PDF 7.8 KB)

Website responses (PDF 1.37 MB)

Department of Health (PDF 8 KB)

Crohn's disease - infliximab (review) and adalimumab: appraisal consultation

Crohn's disease - infliximab (review) and adalimumab: appraisal consultation document information

Crohn's disease - infliximab (review) and adalimumab: evaluation report

Consultee and commentator comments on the ACD

Abbot (PDF 51 KB)

Department of Health (PDF 11 KB)

Hammersmith and Fulham PCT (PDF 13 KB)

National Association for Colitis and Crohn's Disease (PDF 26 KB)

NHS - Quality Improvement Scotland (PDF 44 KB)

Novartis Pharmaceuticals UK (PDF 23 KB)

Royal College of Nursing (PDF 53 KB)

Royal College of Physicians & British Society of Gastroenterology 1 (PDF 76 KB)

Royal College of Physicians & British Society of Gastroenterology 2 (PDF 37 KB)

Schering Plough Ltd (PDF 133 KB)

Welsh Assembly Government (WAG) (PDF 14 KB)

Website responses (PDF 135 KB)

Crohn's disease - infliximab (review) and adalimumab: appraisal consultation

Crohn's disease - infliximab (review) and adalimumab: appraisal consultation document information

Evaluation report

Overview by technical lead (PDF 94 KB)

Crohn's disease - infliximab (review) and adalimumab: consultee and commentator comments for first ACD

Abbott (PDF 173 KB)

Schering - Plough (PDF 72 KB)

NACC

NACC 1 (PDF 65 KB)

NACC 2 (PDF 36 KB)

BSG (PDF 42 KB)

Royal College of Physicians (PDF 62 KB)

Department of health (PDF 7.6 KB)

NHS QIS (PDF 15 KB)

Welsh Assembly Government (PDF 7.8 KB)

Sally Mitton - Clinical expert (PDF 28 KB)

Table of web comments from first ACD (PDF 1.17 MB)

DSU report (version 2) (PDF 372 KB)

Crohn's disease - infliximab (review) and adalimumab: consultee and commentator responses to final DSU Report

Abbott (PDF 74 KB)

BSG and Royal College of Physicians (PDF 32 KB)

Department of Health (PDF 7.6 KB)

NACC (PDF 28 KB)

Royal College of Nursing (PDF 22 KB)

Schering - Plough (PDF 64 KB)

DSU responses to comments from consultees and commentators (PDF 85 KB)

DSU specification - April 2009 (PDF 29 KB)

Crohn's disease - infliximab (review) and adalimumab: DSU report (PDF 61 KB)

Crohn's disease - infliximab (review) and adalimumab: decision support unit specification form (MSWord 137 KB)

Crohn's disease - infliximab (review) and adalimumab: letter to consultees and commentators regarding additional work (PDF 17 KB)

Crohn's disease - infliximab (review) and adalimumab: appraisal consultation 

Crohn's disease - infliximab (review) and adalimumab: appraisal consultation document information

Crohn's disease - infliximab (review) and adalimumab: evaluation report

Assessment report (PDF 2.26 MB)

Overview

Overview (PDF 279 KB)

Overview - Errata - corrected textual errors 1 (PDF 30 KB)

Overview - Errata - corrected textual errors 2 (PDF 18 KB)

Expert written personal statements

Steven (PDF 15 KB)

Mitton (PDF 74 KB)

Ghosh (PDF 46 KB)

Croft (PDF 45 KB)

Manufacturer submissions (executive summary only)

Schering Plough - cost-effectiveness of scheduled maintenance treatment (PDF 157 KB)

Schering Plough - appendices (PDF 456 KB)

Schering Plough - executive summary (PDF 91 KB)

Abbott Laboratories (PDF 61 KB)

Non-manufacturer submission

Royal College of Physicians (PDF 92 KB)

Royal College of Nursing (PDF 34 KB)

National Association for Colitis and Crohn's Disease (NACC) (PDF 222 KB)

Consultee and commentator comments on the assessment report

Sanofi Aventis (PDF 26 KB)

Schering Plough (PDF 104 KB)

Royal College of Nursing (PDF 19 KB)

NHS Quality Improvement Scotland (PDF 13 KB)

National Association for Colitis and Crohn's Disease (NACC) (PDF 22 KB)

Department of Health (PDF 13 KB)

Bedfordshire PCT (PDF 12 KB)

Abbott Laboratories (PDF 707 KB)

Crohn's disease - infliximab (review) and adalimumab: committee meeting information

Crohn's disease - infliximab (review) and adalimumab: cancellation of committee meeting information

Crohn's disease - infliximab (review), certolizumab pegol and adalimumab - Removal of certolizumab pegol letter to Consultees and Commentators (PDF 16 KB)

Crohn's disease - infliximab (review) and adalimumab - Protocol (PDF 229 KB)

Crohn's disease - infliximab (review) and adalimumab: final scope (PDF 118 KB)

Crohn's disease - infliximab (review) and adalimumab : Response to comments on draft scope (PDF 118 KB)

Crohn's disease - infliximab (review) and adalimumab: Response to comments on the provisional matrix (PDF 53 KB)

Crohn's disease - infliximab (review) and adalimumab: Draft scope (PDF 121 KB)

Crohn's disease - infliximab (review) and adalimumab: Provisional matrix of consultees and commentators (PDF 122 KB)

Crohn's disease - infliximab (review) and adalimumab: Letter to consultees and commentators (PDF 48 KB)

Crohn's disease - infliximab (review) and adalimumab: Development up to 30 August 2006 information